ADAPY - Adaptimmune Therapeutics PLC

0.0015
-0.001   -73.333%

Share volume: 612,918
Last Updated: 05-08-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$0.00
0.00
-0.42%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
-92.50%
3 Months
-95.00%
6 Months
-94.77%
1 Year
-96.67%
2 Year
-96.67%
Key data
Stock price
$0.00
P/E Ratio 
N/A
DAY RANGE
$0.00 - $0.01
EPS 
N/A
52 WEEK RANGE
$0.00 - $0.07
52 WEEK CHANGE
-$96.67
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$208,094
AVERAGE 30 VOLUME 
$298,710
Company detail
CEO: Adrian Rawcliffe
Region: US
Website: adaptimmune.com
Employees: 490
IPO year: 2015
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)

Recent news